Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-02-18
DOI
10.1038/s41416-020-01247-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Estimating Risk of Recurrence for Early Breast Cancer: Integrating Clinical and Genomic Risk
- (2019) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
- (2019) Ivana Sestak et al. BREAST CANCER RESEARCH AND TREATMENT
- Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial
- (2019) Angela Mariotto et al. JNCI-Journal of the National Cancer Institute
- Methods for Development of the European Commission Initiative on Breast Cancer Guidelines
- (2019) Holger J. Schünemann et al. ANNALS OF INTERNAL MEDICINE
- Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis
- (2019) Sue Harnan et al. HEALTH TECHNOLOGY ASSESSMENT
- RE: Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial
- (2019) Paolo Giorgi Rossi et al. JNCI-Journal of the National Cancer Institute
- Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
- (2019) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update—Integration of Results From TAILORx
- (2019) Fabrice Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy
- (2019) Joseph A. Sparano et al. JAMA Oncology
- Breast Cancer Screening and Diagnosis: A Synopsis of the European Breast Guidelines
- (2019) Holger J. Schünemann et al. ANNALS OF INTERNAL MEDICINE
- Oncotype DX Breast Cancer recurrence score resists inter-assay reproducibility with RT2-Profiler Multiplex RT-PCR
- (2019) Verena Schildgen et al. Scientific Reports
- Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe
- (2018) E.J. Blok et al. CANCER TREATMENT REVIEWS
- Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal
- (2018) Shi-Yi Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
- (2018) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer
- (2018) Ivana Sestak et al. JAMA Oncology
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
- (2017) Ian Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2016) Lyndsay N. Harris et al. JOURNAL OF CLINICAL ONCOLOGY
- 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
- (2016) Fatima Cardoso et al. NEW ENGLAND JOURNAL OF MEDICINE
- GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines
- (2016) Pablo Alonso-Coello et al. BMJ-British Medical Journal
- ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
- (2016) Jonathan AC Sterne et al. BMJ-British Medical Journal
- GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines
- (2016) Pablo Alonso-Coello et al. BMJ-British Medical Journal
- ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
- (2016) Jonathan AC Sterne et al. BMJ-British Medical Journal
- Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype
- (2015) M. Gnant et al. ANNALS OF ONCOLOGY
- Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients
- (2015) Fausto Petrelli et al. BREAST CANCER RESEARCH AND TREATMENT
- Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score
- (2015) Ivana Sestak et al. JOURNAL OF CLINICAL ONCOLOGY
- Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France
- (2015) Gregory Katz et al. PLoS One
- Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis
- (2014) S Ward et al. HEALTH TECHNOLOGY ASSESSMENT
- Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise
- (2013) H. J. Schunemann et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer
- (2013) J.A. Davidson et al. EUROPEAN JOURNAL OF CANCER
- Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy
- (2013) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost-Effectiveness of the 21-Gene Assay for Guiding Adjuvant Chemotherapy Decisions in Early Breast Cancer
- (2013) Mike Paulden et al. VALUE IN HEALTH
- Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan
- (2012) Masahide Kondo et al. BREAST CANCER RESEARCH AND TREATMENT
- Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer
- (2012) S Barton et al. BRITISH JOURNAL OF CANCER
- Developing clinical practice guidelines: types of evidence and outcomes; values and economics, synthesis, grading, and presentation and deriving recommendations
- (2012) Steven Woolf et al. Implementation Science
- Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting
- (2012) J. U. Blohmer et al. JOURNAL OF MEDICAL ECONOMICS
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
- (2011) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer
- (2011) Jack Cuzick et al. JOURNAL OF CLINICAL ONCOLOGY
- The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer
- (2010) Michael Knauer et al. BREAST CANCER RESEARCH AND TREATMENT
- GRADE guidelines: 2. Framing the question and deciding on important outcomes
- (2010) Gordon H. Guyatt et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
- (2009) Kathy S Albain et al. LANCET ONCOLOGY
- The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study
- (2008) Stella Mook et al. BREAST CANCER RESEARCH AND TREATMENT
- Validation of 70-gene prognosis signature in node-negative breast cancer
- (2008) J. M. Bueno-de-Mesquita et al. BREAST CANCER RESEARCH AND TREATMENT
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More